Literature DB >> 22043900

Interleukin-32 enhances cytotoxic effect of natural killer cells to cancer cells via activation of death receptor 3.

Mi H Park1, Min J Song, Min-Chul Cho, Dong C Moon, Do Y Yoon, Sang B Han, Jin T Hong.   

Abstract

Studies have demonstrated that the anti-tumour effect of natural killer (NK) cells is successful for patients with several cancers. Although interleukin-32 (IL-32) is endogenously expressed in NK cells, cytolytic function of NK cells against cancer cells has not been fully demonstrated. In the present study, we found that the growth of cancer cells was suppressed when colon cancer cells or prostate cancer cells were co-cultured with NK-92 cells, an NK cell line. We also found that the expression of tumour necrosis factor receptor 2 and death receptor 3 (DR3) was increased in PC3 cells, and the expression of FAS and DR3 was increased in SW620 cells by co-culture with NK-92 cells. However, cancer cell growth inhibition and IL-32 expression were abolished when cancer cells were co-cultured with NK cells transfected with small interfering (si) RNA of IL-32. DR3 expression was also diminished by co-culture with IL-32-specific siRNA-transfected NK-92 cells. Expression of APO3L, a ligand of DR3, was elevated in NK cells that were co-cultured with cancer cells. It was also found that expression of apoptosis-related proteins such as cleaved caspase-3 and bax was increased in cancer cells co-cultured with NK-92 cells, but their expression was abolished by co-culture with IL-32 siRNA-transfected NK-92 cells. Moreover, knockdown of DR3 in co-culture of NK-92 cells with cancer cells by siRNA or antibodies of DR3 and APO3L reversed the growth inhibitory effect of NK-92 cells. In conclusion, our study showed that IL-32 enhanced the cytotoxic effect of NK-92 cells on the cancer cells through activation of DR3 and caspase-3.
© 2011 The Authors. Immunology © 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22043900      PMCID: PMC3246653          DOI: 10.1111/j.1365-2567.2011.03513.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  53 in total

Review 1.  New aspects of natural-killer-cell surveillance and therapy of cancer.

Authors:  Mark J Smyth; Yoshihiro Hayakawa; Kazuyoshi Takeda; Hideo Yagita
Journal:  Nat Rev Cancer       Date:  2002-11       Impact factor: 60.716

Review 2.  Cell surface Death Receptor signaling in normal and cancer cells.

Authors:  Nesrin Ozören; Wafik S El-Deiry
Journal:  Semin Cancer Biol       Date:  2003-04       Impact factor: 15.707

3.  TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator.

Authors:  Thi Sau Migone; Jun Zhang; Xia Luo; Li Zhuang; Cecil Chen; Bugen Hu; June S Hong; James W Perry; Su Fang Chen; Joe X H Zhou; Yun Hee Cho; Stephen Ullrich; Palanisamy Kanakaraj; Jeffrey Carrell; Ernest Boyd; Henrik S Olsen; Gang Hu; Laurie Pukac; Ding Liu; Jian Ni; Sunghee Kim; Reiner Gentz; Ping Feng; Paul A Moore; Steve M Ruben; Ping Wei
Journal:  Immunity       Date:  2002-03       Impact factor: 31.745

Review 4.  NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity.

Authors:  Per A Albertsson; Per H Basse; Marianne Hokland; Ronald H Goldfarb; J Fred Nagelkerke; Ulf Nannmark; Peter J K Kuppen
Journal:  Trends Immunol       Date:  2003-11       Impact factor: 16.687

5.  Molecular characterization of defective antigen processing in human prostate cancer.

Authors:  M G Sanda; N P Restifo; J C Walsh; Y Kawakami; W G Nelson; D M Pardoll; J W Simons
Journal:  J Natl Cancer Inst       Date:  1995-02-15       Impact factor: 13.506

6.  Death receptor 3 (DR3) gene duplication in a chromosome region 1p36.3: gene duplication is more prevalent in rheumatoid arthritis.

Authors:  K Osawa; N Takami; K Shiozawa; A Hashiramoto; S Shiozawa
Journal:  Genes Immun       Date:  2004-09       Impact factor: 2.676

Review 7.  TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR/Fn14 receptor.

Authors:  Steven R Wiley; Jeffrey A Winkles
Journal:  Cytokine Growth Factor Rev       Date:  2003 Jun-Aug       Impact factor: 7.638

Review 8.  TRAIL and apoptosis induction by TNF-family death receptors.

Authors:  Shulin Wang; Wafik S El-Deiry
Journal:  Oncogene       Date:  2003-11-24       Impact factor: 9.867

9.  The role of Toll-like receptor 4 versus interleukin-12 in immunity to respiratory syncytial virus.

Authors:  Stephan Ehl; Ruth Bischoff; Tobias Ostler; Simone Vallbracht; Jürgen Schulte-Mönting; Alexander Poltorak; Marina Freudenberg
Journal:  Eur J Immunol       Date:  2004-04       Impact factor: 5.532

10.  A contribution of mouse dendritic cell-derived IL-2 for NK cell activation.

Authors:  Francesca Granucci; Ivan Zanoni; Norman Pavelka; Serani L H Van Dommelen; Christopher E Andoniou; Filippo Belardelli; Mariapia A Degli Esposti; Paola Ricciardi-Castagnoli
Journal:  J Exp Med       Date:  2004-08-02       Impact factor: 14.307

View more
  23 in total

1.  On death receptor 3 and its ligands….

Authors:  Eddie C Y Wang
Journal:  Immunology       Date:  2012-09       Impact factor: 7.397

2.  Transcription of Nrdp1 by the androgen receptor is regulated by nuclear filamin A in prostate cancer.

Authors:  Rosalinda M Savoy; Liqun Chen; Salma Siddiqui; Frank U Melgoza; Blythe Durbin-Johnson; Christiana Drake; Maitreyee K Jathal; Swagata Bose; Thomas M Steele; Benjamin A Mooso; Leandro S D'Abronzo; William H Fry; Kermit L Carraway; Maria Mudryj; Paramita M Ghosh
Journal:  Endocr Relat Cancer       Date:  2015-03-10       Impact factor: 5.678

3.  Interplay between thyroid cancer cells and macrophages: effects on IL-32 mediated cell death and thyroid cancer cell migration.

Authors:  Yvette J E Sloot; Katrin Rabold; Thomas Ulas; Dennis M De Graaf; Bas Heinhuis; Kristian Händler; Joachim L Schultze; Mihai G Netea; Johannes W A Smit; Leo A B Joosten; Romana T Netea-Maier
Journal:  Cell Oncol (Dordr)       Date:  2019-06-14       Impact factor: 6.730

Review 4.  Role of interleukin-32 in chronic rhinosinusitis.

Authors:  Anjeni Keswani; Robert C Kern; Robert P Schleimer; Atsushi Kato
Journal:  Curr Opin Allergy Clin Immunol       Date:  2013-02

Review 5.  Novel insights into the biology of interleukin-32.

Authors:  Leo A B Joosten; Bas Heinhuis; Mihai G Netea; Charles A Dinarello
Journal:  Cell Mol Life Sci       Date:  2013-03-06       Impact factor: 9.261

6.  The role of IL-32 in cutaneous T-cell lymphoma.

Authors:  Hiraku Suga; Makoto Sugaya; Tomomitsu Miyagaki; Makiko Kawaguchi; Hideki Fujita; Yoshihide Asano; Yayoi Tada; Takafumi Kadono; Shinichi Sato
Journal:  J Invest Dermatol       Date:  2013-11-13       Impact factor: 8.551

7.  Impact of intra-tumoral IL17A and IL32 gene expression on T-cell responses and lymph node status in breast cancer patients.

Authors:  Shreyas Bhat; Nilesh Gardi; Sujata Hake; Nirupama Kotian; Sharada Sawant; Sadhana Kannan; Vani Parmar; Sangeeta Desai; Amit Dutt; Narendra N Joshi
Journal:  J Cancer Res Clin Oncol       Date:  2017-05-03       Impact factor: 4.553

Review 8.  The use of microRNA by human viruses: lessons from NK cells and HCMV infection.

Authors:  Tal Goldberger; Ofer Mandelboim
Journal:  Semin Immunopathol       Date:  2014-09-19       Impact factor: 11.759

9.  Growth Inhibitory Effect of (E)-2,4-bis(p-hydroxyphenyl)-2-Butenal Diacetate through Induction of Apoptotic Cell Death by Increasing DR3 Expression in Human Lung Cancer Cells.

Authors:  Ung-Soo Lee; Jung Ok Ban; Eung Tae Yeon; Hee Pom Lee; Venkatareddy Udumula; Young Wan Ham; Jin Tae Hong
Journal:  Biomol Ther (Seoul)       Date:  2012-11       Impact factor: 4.634

10.  NKP30-B7-H6 Interaction Aggravates Hepatocyte Damage through Up-Regulation of Interleukin-32 Expression in Hepatitis B Virus-Related Acute-On-Chronic Liver Failure.

Authors:  Yong Zou; Junjie Bao; Xingfei Pan; Ying Lu; Sihong Liao; Xicheng Wang; Guoying Wang; Dongjun Lin
Journal:  PLoS One       Date:  2015-08-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.